Forbion overview
Stories about Forbion
Forbion is raising new fund to address 'planetary health challenges'
Forbion, a life sciences venture capital firm, has held a first close on €75m for Forbion BioEconomy Fund I, which is targeting €150m.
Biotech company enGene to go public in Forbion-sponsored SPAC merger
Upon closing of the deal, the combined company will be named enGene Holdings, whose common shares are expected to be listed on the Nasdaq.
Forbion leads $37m round for Oxular
Oxular, a retinal therapeutics development company, has raised $37 million in funding.
Inversago Pharma picks up $35m in Forbion-led Series B
Montreal-based Inversago Pharma, a peripheral CB1 blockade company, has raised US$35 million in Series B funding.
German biopharma company Omeicos Therapeutics snags Series C funding
Berlin-based Omeicos Therapeutics, a biopharmaceutical company, has secured 17 million euros in Series C funding. Forbion led the round.
Forbion Fund IV raises 270 mln euros
Forbion said July 11 that its fourth flagship fund closed on 270 million euros ($316.3 million), surpassing its 250 million euros target. Forbion IV will focus on biotech and seek to invest in about 15 companies, mainly in the EU and UK.
Forbion contact information
Offices
Gooimeer 2-35, Naarden, 1411, NetherlandsContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Joy Faucher | Job titleGeneral Partner | LocationNaarden, Netherlands | Email  ------- |
| Key ContactMr. Alexander Hoffmann | Job titleGeneral Partner | LocationNaarden, Netherlands | Email ----------- |
| Key ContactMr. Robbert Van De Griendt | Job titleGeneral Partner, Investor Relations and Impact | LocationNaarden, Netherlands | Email ----- |
| Key ContactMs. Rachelle Young | Job titleInvestor Relations Director | LocationNaarden, Netherlands | Email ----- |
Forbion funds managed
Closed funds: 21
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ------- | Close dateOct 2026 | Strategy ------- | |
Fund size ----------- | Close dateOct 2026 | Strategy --------- | |
Fund size ------- | Close dateOct 2025 | Strategy ---------- | |
Stories that mention Forbion
A big LP you need to know
Yup Kim, CIO of Texas Municipal Retirement System, is a fan of venture capital and says the $44bn public pension may invest 'several hundreds of millions' per year in the asset class.
Yup Kim’s bold vision for Texas Municipal Retirement System
The new CIO of the $44bn public pension system is pushing hard into PE, and VC is a big part of his plan.
DOWNLOAD: VC fundraising hits six-year low
Venture capital funds closed on $104.7bn worldwide in 2024, or 18% less than they raised in 2023, according to our annual Global Venture Capital Fundraising Report.
Swiss biotech firm grabs $147m Series B
The investors include EQT Life Sciences, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Three big LPs are warming to growth equity
Alaska Permanent, CalPERS and New Mexico SIC are more interested in growth equity since valuations have come down for growth-stage companies.
CalPERS is already putting more money into VC and growth
CalPERS committed a combined $2.1 billion to 13 growth equity and VC funds in the third quarter of 2023, a new report shows.
How institutions are bridging Europe’s scale-up gap
European venture funds and founders have had their own fundraising challenges.
Side Letter: PE's entry barrier; Pictet's double close; Niche index update
Monday is a bank holiday in the UK due to King Charles's coronation this weekend, so Side Letter will return on Tuesday. For now, institutional investors face a knowledge gap when pondering an entry into private markets. Plus: nice news for niche investors. Here’s today's brief, for our valued subscribers only.